Anthony D. Ho

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood

Wolfgang Wagner, Frederik Wein, Anja Seckinger et al. · Experimental Hematology · 2005 · 1.3K citations · Full text

Life Sciences, Biotechnology, Cell Biology +17

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert et al. · The Lancet Oncology · 2008 · 1.1K citations

Medicine, Immunology, Oncology +7

Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process

Wolfgang Wagner, Patrick Horn, M. Castoldi et al. · PLoS ONE · 2008 · 1.1K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

Human haematopoietic stem cell lineage commitment is a continuous process

Lars Velten, Simon Haas, Simon Raffel et al. · Nature Cell Biology · 2017 · 928 citations · Full text

Life Sciences, Cell Biology, Hematology +12